Samsara Biocapital, L.p. - Net Worth and Insider Trading

Samsara Biocapital, L.p. Net Worth

The estimated net worth of Samsara Biocapital, L.p. is at least $4 Million dollars as of 2024-11-29. Samsara Biocapital, L.p. is the 10% Owner of Graphite Bio Inc and owns about 1,213,866 shares of Graphite Bio Inc (GRPH) stock worth over $4 Million. Details can be seen in Samsara Biocapital, L.p.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Samsara Biocapital, L.p. has not made any transactions after 2022-04-12 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Samsara Biocapital, L.p.

Samsara Biocapital, L.p. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Samsara Biocapital, L.p. owns 3 companies in total, including Graphite Bio Inc (GRPH) , Mineralys Therapeutics Inc (MLYS) , and Scholar Rock Holding Corp (SRRK) .

Click here to see the complete history of Samsara Biocapital, L.p.’s form 4 insider trades.

Insider Ownership Summary of Samsara Biocapital, L.p.

Ticker	Comapny	Transaction Date	Type of Owner
GRPH	Graphite Bio Inc	2022-04-12	10 percent owner
MLYS	Mineralys Therapeutics Inc	2023-02-09	10 percent owner
SRRK	Scholar Rock Holding Corp	2022-06-22	10 percent owner

Samsara Biocapital, L.p. Latest Holdings Summary

Samsara Biocapital, L.p. currently owns a total of 1 stock. Samsara Biocapital, L.p. owns 1,213,866 shares of Graphite Bio Inc (GRPH) as of April 12, 2022, with a value of $4 Million.

Latest Holdings of Samsara Biocapital, L.p.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
GRPH	Graphite Bio Inc	2022-04-12	1,213,866	3.18	3,860,094

Holding Weightings of Samsara Biocapital, L.p.

Samsara Biocapital, L.p. Form 4 Trading Tracker

According to the SEC Form 4 filings, Samsara Biocapital, L.p. has made a total of 7 transactions in Graphite Bio Inc (GRPH) over the past 5 years, including 7 buys and 0 sells. The most-recent trade in Graphite Bio Inc is the acquisition of 60,638 shares on April 12, 2022, which cost Samsara Biocapital, L.p. around $2 Million.

Insider Trading History of Samsara Biocapital, L.p.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Samsara Biocapital, L.p. Trading Performance

GuruFocus tracks the stock performance after each of Samsara Biocapital, L.p.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Samsara Biocapital, L.p. is -28.42%. GuruFocus also compares Samsara Biocapital, L.p.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Samsara Biocapital, L.p. within 3 months outperforms 1 times out of 7 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Samsara Biocapital, L.p.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Samsara Biocapital, L.p.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 7 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-5.06
Relative Return to S&P 500(%)	-4.31

Samsara Biocapital, L.p. Ownership Network

Ownership Network List of Samsara Biocapital, L.p.

No Data

Ownership Network Relation of Samsara Biocapital, L.p.

Samsara Biocapital, L.p. Owned Company Details

What does Graphite Bio Inc do?

Who are the key executives at Graphite Bio Inc?

Samsara Biocapital, L.p. is the 10 percent owner of Graphite Bio Inc. Other key executives at Graphite Bio Inc include 10 percent owner Ecor1 Capital, Llc , CHIEF BUSINESS OFFICER Phil Gutry , and Chief Financial Officer Alethia Young .

Graphite Bio Inc (GRPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Graphite Bio Inc (GRPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Graphite Bio Inc (GRPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Graphite Bio Inc (GRPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Graphite Bio Inc Insider Transactions

No Available Data

What does Mineralys Therapeutics Inc do?

Who are the key executives at Mineralys Therapeutics Inc?

Samsara Biocapital, L.p. is the 10 percent owner of Mineralys Therapeutics Inc. Other key executives at Mineralys Therapeutics Inc include Chief Medical Officer David Malcom Rodman , director & Chief Executive Officer Jon Congleton , and CFO & Chief Bus. Off. and Secy. Adam Scott Levy .

Mineralys Therapeutics Inc (MLYS) Insider Trades Summary

Over the past 18 months, Samsara Biocapital, L.p. made no insider transaction in Mineralys Therapeutics Inc (MLYS). Other recent insider transactions involving Mineralys Therapeutics Inc (MLYS) include a net sale of 142,377 shares made by Jon Congleton , a net sale of 262,849 shares made by David Malcom Rodman , and a net sale of 118,329 shares made by Adam Scott Levy .

In summary, during the past 3 months, insiders sold 56,536 shares of Mineralys Therapeutics Inc (MLYS) in total and bought 0 shares, with a net sale of 56,536 shares. During the past 18 months, 1,084,305 shares of Mineralys Therapeutics Inc (MLYS) were sold and 566,305 shares were bought by its insiders, resulting in a net sale of 518,000 shares.

Mineralys Therapeutics Inc (MLYS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mineralys Therapeutics Inc Insider Transactions

No Available Data

What does Scholar Rock Holding Corp do?

Who are the key executives at Scholar Rock Holding Corp?

Samsara Biocapital, L.p. is the 10 percent owner of Scholar Rock Holding Corp. Other key executives at Scholar Rock Holding Corp include Chief Medical Officer Jing L. Marantz , 10 percent owner Invus Public Equities, L.p. , and Chief Commercial Officer Tracey Sacco .

Scholar Rock Holding Corp (SRRK) Insider Trades Summary

Over the past 18 months, Samsara Biocapital, L.p. made no insider transaction in Scholar Rock Holding Corp (SRRK). Other recent insider transactions involving Scholar Rock Holding Corp (SRRK) include a net sale of 336,643 shares made by Edward H Myles , a net sale of 35,372 shares made by Mo Qatanani , and a net sale of 13,709 shares made by Caryn Parlavecchio .

In summary, during the past 3 months, insiders sold 1,980,509 shares of Scholar Rock Holding Corp (SRRK) in total and bought 0 shares, with a net sale of 1,980,509 shares. During the past 18 months, 2,129,751 shares of Scholar Rock Holding Corp (SRRK) were sold and 6,579,493 shares were bought by its insiders, resulting in a net purchase of 4,449,742 shares.

Scholar Rock Holding Corp (SRRK)'s detailed insider trading history can be found in Insider Trading Tracker table.

Scholar Rock Holding Corp Insider Transactions

No Available Data

Samsara Biocapital, L.p. Mailing Address

Above is the net worth, insider trading, and ownership report for Samsara Biocapital, L.p.. You might contact Samsara Biocapital, L.p. via mailing address: 628 Middlefield Road, Palo Alto Ca 94301.

Discussions on Samsara Biocapital, L.p.

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.